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Sarcosine, an endogenous amino acid, is a competitive inhibitor of the type I glycine
transporter and an N-methyl-D-aspartate receptor (NMDAR) coagonist. Recently, we
found that sarcosine, an NMDAR enhancer, can improve depression-related behaviors in
rodents and humans. This result differs from previous studies, which have reported antide-
pressant effects of NMDAR antagonists. The mechanisms underlying the therapeutic
response of sarcosine remain unknown. This study examines the role of mammalian target
of rapamycin (mTOR) signaling and α-amino-3-hydroxy-5-methylisoxazole-4-propionate
receptor (AMPAR) activation, which are involved in the antidepressant-like effects of sev-
eral glutamatergic systemmodulators. The effects of sarcosine in a forced swim test (FST)
and the expression levels of phosphorylated mTOR signaling proteins were examined
in the absence or presence of mTOR and AMPAR inhibitors. In addition, the influence
of sarcosine on AMPAR trafficking was determined by analyzing the phosphorylation of
AMPAR subunit GluR1 at the PKA site (often considered an indicator for GluR1membrane
insertion in neurons). A single injection of sarcosine exhibited antidepressant-like effects in
rats in the FST and rapidly activated the mTOR signaling pathway, which were significantly
blocked by mTOR inhibitor rapamycin or the AMPAR inhibitor 2,3-dihydroxy-6-nitro-
7-sulfamoyl-benzo(f)quinoxaline (NBQX) pretreatment. Moreover, NBQX pretreatment
eliminated the ability of sarcosine to stimulate the phosphorylated mTOR signaling
proteins. Furthermore, GluR1 phosphorylation at its PKA site was significantly increased
after an acute in vivo sarcosine treatment. The results demonstrated that sarcosine exerts
antidepressant-like effects by enhancing AMPAR–mTOR signaling pathway activity and
facilitating AMPAR membrane insertion.
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Highlights
– A single injection of sarcosine rapidly exerted antidepressant-like effects with a
concomitant increase in the activation of the mammalian target of rapamycin mTOR
signaling pathway.
– The antidepressant-like effects of sarcosine occur through the activated
AMPAR–mTOR signaling pathway.
– Sarcosine could enhance AMPAR membrane insertion via an AMPAR throughput.
Keywords: sarcosine, mTOR, NMDA, AMPA, depression
Introduction
Current antidepressants primarily comprise monoamine-
targeting agents and have limited efficacy (Trivedi et al., 2006;
Fekadu et al., 2009; Rizvi et al., 2014). Recently, modulation
of the glutamatergic system has become an attractive strategy
for discovering new-generation antidepressants (Shimizu-
Sasamata et al., 1996; Skolnick, 1999; Krystal et al., 2002;
Stewart and Reid, 2002; Hashimoto, 2011; Tokita et al., 2012).
For example, ketamine, an N-methyl--aspartate receptor
(NMDAR) antagonist, rapidly and sustainably ameliorates
depressive symptoms in patients with major depression (Zarate
et al., 2006b,c). Several preclinical reports have also indicated
that NMDAR-antagonizing drugs, such as ketamine, MK-801,
AP7, CGP37849, and CGP39551, have antidepressant-like
properties in various animal models of depression (Kugaya and
Sanacora, 2005; Maeng et al., 2008; Li et al., 2010). Sarcosine,
an endogenous amino acid, is a competitive inhibitor of the
type I glycine transporter (GlyT1) (Smith et al., 1992) and
an NMDAR coagonist (Zhang et al., 2009). Because of these
two properties, sarcosine can enhance NMDAR function. We
previously conducted both rodent behavior tests and a trial of
sarcosine treatment for major depression and demonstrated that
sarcosine treatment elicits similar antidepressant-like effects
in both acute and chronic stress models of depression and
achieved a much higher remission rate than did a standard
selective serotonin reuptake inhibitor (SSRI) treatment for major
depression (Huang et al., 2013). Preclinical studies have also
shown that the administration of other NMDAR enhancers,
such as a reversible glycine transporter inhibitor, SSR504734,
and an NMDAR coagonist, -serine, has antidepressant and
anxiolytic effects in depression and anxiety models (Depoortere
et al., 2005; Malkesman et al., 2012). Studies have elucidated that
the rapid activation of the mammalian target of rapamycin
(mTOR) signaling pathway through stimulation of the
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
receptor (AMPAR) is a major mechanism of the NMDAR
antagonist ketamine in exerting its rapid antidepressant
effects (Maeng et al., 2008; Li et al., 2010). Similarly, studies have
suggested that some glutamatergic systemmodulators, such as the
metabotropic glutamate receptor mGluR2/3 antagonist LY341495,
mGluR5 antagonist MTEP, and mGluR7 agonist AMN082,
produce antidepressant-like effects through increased activation
of mTOR, and some studies have shown that the effects of some of
them are also dependent on AMPAR activation (Koike and Chaki,
2014; Palucha-Poniewiera et al., 2014). Until now, the molecular
mechanisms underlying the antidepressant effects of sarcosine
have been unclear. The present study was conducted to determine
whether sarcosine increases the activation of mTOR signaling or
AMPAR and whether the antidepressant-like effects of sarcosine
require the stimulation of mTOR signaling or AMPAR.
Therefore, the effects of sarcosine in a forced swim test
(FST) and the expression levels of phospho-mTOR (pmTOR),
phosphor-extracellular signal-regulated protein kinase (pERK),
and phospho-Akt (pAkt) in the hippocampus, an area directly
implicated in mood regulation and antidepressant effective-
ness (Nestler et al., 2002; Campbell and Macqueen, 2004) were
examined in the absence or presence of an mTOR antagonist,
rapamycin, and the selective AMPAR antagonist 2,3-dihydroxy-6-
nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX). In addition, we
assessed the possible involvement of AMPAR trafficking in the
effects of sarcosine on mTOR activation by focusing on AMPAR
membrane insertion, known to be induced by glycine (Lu et al.,
2001) and involved in antidepressant effects (Du et al., 2007). The
present study was specifically designed to obtain results, for the
first time, of potential antidepressant-like effects of sarcosine on
the mTOR signal pathway and AMPAR for understanding the
molecular events caused by sarcosine.
Materials and Methods
Animals
Male Wistar rats, weighing 250–350 g, were used. Five rats were
housed per cage, with food and water available ad libitum in the
laboratory animal center, and maintained on a 12-h light–dark
cycle (light, 07:00–19:00) at 23°C 1°C and in a 60% humidity-
controlled environment. After at least a seven-day acclimation
period in the center, the rats were transferred to the testing
room and were immediately used for subsequent experiments.
The study protocol was approved by the Institutional Animal Care
and Use Committee of China Medical University, Taiwan.
Study Design
Experimental Protocols
Sarcosine (Merck Millipore, #807666), rapamycin (Toku-E,
#R001), and NBQX (Tocris, #0373) were dissolved in saline and
injected intraperitoneally (i.p.) in a volume of 0.01mL/g of body
weight. The naïve rats were randomly treated with saline (control)
or sarcosine (560mg/kg, i.p.) [as previously reported in our earlier
study (Huang et al., 2013) to evoke antidepressant-like effects].
The FST was performed 30min after treatment. In addition,
rats first had a 15-min conditioning swim 24 h before the FST
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FIGURE 1 | Schemata demonstrating the timeline of the experiments
for drugs administrations, behavioral tests, and time of sacrifice for
western blots analysis. For acute sarcosine administration (A,B), rats were
given saline or sarcosine (560mg/kg, i.p.) once. The forced swim test (FST)
was conducted 30min later (A). At 24 h before FST, rats had a 15-min
conditioning swim. To evaluate the general locomotor activity, rats were
administrated with saline or sarcosine (560mg/kg, i.p.) once. The elevated
plus-maze test (EPM) was conducted 30min later (B). Immediately after EPM,
rats were sacrificed and then rapidly decapitated. The hippocampus was
removed for biochemical analysis (B). For acute sarcosine administration in
the absence or presence of mTOR and AMPAR inhibitors (C,D), either AMPA
inhibitor (NBQX, 10mg/kg, i.p.) or mTOR pathway inhibitor (rapamycin,
20mg/kg, i.p.) was administrated 30min before sarcosine (560mg/kg, i.p.) or
saline treatment. At 30min after last injection, rats were then tested in an FST
paradigm (C). In a separate study (D), naïve rats were randomly treated with
either AMPA inhibitor (NBQX, 10mg/kg, i.p.) or mTOR pathway inhibitor
(rapamycin, 20mg/kg, i.p.) was administrated 30min before sarcosine
(560mg/kg, i.p.) treatment. Thirty minutes after last injection, rats were
sacrificed and then rapidly decapitated. The hippocampus was removed for
biochemical analysis.
(Figure 1A). Each experimental group comprised 10 rats. To
evaluate the general locomotor activity, in another experiment,
naïve rats were treated with saline or sarcosine (560mg/kg, i.p.),
and the elevated plus-maze test (EPM) was conducted 30min
later (Figure 1B). Each experimental group comprised eight rats.
Immediately after EPM, four rats in each group were sacrificed
using an intramuscular injection of mixture of zoletil (30mg/kg)
and xylazine (10mg/kg) followed by immediate decapitation. The
hippocampus was removed and stored at  80°C for biochemical
analysis.
In addition, the mTOR pathway inhibitor rapamycin or
AMPAR inhibitor NBQX was used to determine whether sarco-
sine might induce antidepressant-like effects through these sig-
naling pathways (Figure 1C). Saline, rapamycin (20mg/kg, i.p.)
(Cleary et al., 2008), or NBQX (10mg/kg, i.p.) (Maeng et al.,
2008) was administered 30min before sarcosine (560mg/kg, i.p.)
or saline injection. Thirty minutes after the final injection, the
rats were tested in an FST paradigm. Each experimental group
comprised eight to nine rats. In a separate experiment, another
16 naïve rats were randomly divided into 4 groups, with 4 rats
per group (Figure 1D). Saline, rapamycin (20mg/kg, i.p.), or
NBQX (10mg/kg, i.p.) was administered 30min before sarcosine
(560mg/kg, i.p.) injection. Thirtyminutes after the final injection,
the rats were sacrificed using an intramuscular injection of a
mixture of zoletil (30mg/kg) and xylazine (10mg/kg), followed
by immediate decapitation. The hippocampus was removed and
stored at 80°C for biochemical analysis.
Behavioral Assays
Forced Swim Test
The FST was performed in an acrylic cylinder (diameter, 20 cm;
height, 40 cm) filled to a height of 30 cmwith 25°Cwater. Rats first
had a 15-min conditioning swim before being placed in the swim-
ming apparatus again 24 h later. Their behavior was monitored
for 5min after the administration of drugs or 0.9% saline (Porsolt
et al., 1977; Cryan et al., 2005). The total periods of immobility
during the 5-min testing period were recorded using the EthoVi-
sion Basic V 3.1 program (Noldus,Wageningen, Netherlands) and
confirmed through direct observation. The effects of medication
were evaluated using a computer and traditionalmanualmethods.
For computer scoring, immobility was set at 15% and a fixed
averaging interval of 1 s was used for smoothing the mobility
parameter. These settings were used to automatically acquire the
activity of all rats in the FST. Manual scoring of the behavioral
patterns was performed by an investigator who was blinded to the
experimental conditions of the animals. We used a time-sampling
technique whereby the predominant behavior in each 5-s period
of the 300-s test was recorded (Detke et al., 1997). Climbing
behaviors comprised upward movements of the forepaws along
the side of the swim chamber. Swimming behavior was defined as
movement (typically horizontal) throughout the swim chamber,
which typically involved crossing into another quadrant. Immo-
bility was assignedwhen no additional activity was observed other
than that required to keep the rat’s head above water.
Elevated Plus-Maze Test
The EPM was placed in a dark room with a localized dim light
(3 5W) facing the apparatus and mounted 130 cm above the
EPM’s surface. The rats were placed in the central square and
their behaviors were monitored for 5min after the administration
of drugs or 0.9% saline. The numbers of open and closed arm
entries and distance moved were recorded using the EthoVision
Basic V 3.1 program. The total closed arm entries and distances
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FIGURE 2 | The behaviors and representative Western blotting of rats in
forced swim test after acute administration with saline or sarcosine
(560mg/kg, i.p.). In the acute treatment scored by computer (A), the rats
received a single injection of sarcosine prior to FST showed a significant
reduction in percentage of immobility time. In the acute treatment scored
manually (B), the rats received a single injection of sarcosine prior to FST
showed a considerable reduction in immobility and an increase in climbing. The
general activity [(C), numbers of closed arm entries and (D), total distance
moved] of rats in the elevated plus maze (EPM) after acute administration with
saline or sarcosine. The total closed arm entries (C) and distance moved (D) in
EPM were measured to determine if sarcosine could produce a general increase
in general locomotor activity that could yield a false-positive result on the FST.
At the doses tested, none increased locomotor activity. Western blots analysis
shows a notably increased expression of pmTOR, pERK, and pAkt in rat
hippocampus following acute sarcosine treatment (E). The densitometry
analysis of the blot (normalized to β-actin) verifies the enhanced activity of
pmTOR (F), pERK (G), and pAkt (H) in each group of the experiments.
(*p<0.05; **p<0.01; ***p<0.001 compared with saline-treated group as
assessed by t-test, Values shown are meanSEM, n= 10 for FST; n= 8 for
EPM; n= 4 for western blots analysis per group).
moved were analyzed quantitatively as a relatively pure index of
locomotor activity (Rodgers and Johnson, 1995; Hogg, 1996).
Western Blotting
Previously described methods for tissue processing and West-
ern blotting were followed (Encinas et al., 2004). The dissected
brain tissue was frozen in liquid nitrogen and then homoge-
nized with 100mL of lysis buffer by using a grinder on ice.
Subsequently, 100µg of solubilized proteins were separated using
electrophoresis on a 10% polyacrylamide gel, transferred to nitro-
cellulose membranes, and stained with Ponceau Red for con-
firming equal protein loading. The membranes were blocked
with 5% non-fat dry milk for 1 h, and then immunoreacted
overnight at 4°C with rabbit polyclonal antiphospho-mTOR (Cell
Signaling, #2971S) at a dilution of 1:1000, rabbit monoclonal
anti-pERK (for detecting ERK1/2 MAPKs phosphorylated at
Thr202/Tyr204 and Thr185/Tyr187, Millipore, #05-797R) at a
dilution of 1:1000, rabbit polyclonal antiphospho-Akt1/PKBαser-
473 (Millipore, #05-669) at a dilution of 1:1000, or rabbit poly-
clonal antiphospho-AMPA GluR1 Ser845 (Sigma, #A4477) at a
dilution of 1:1000 primary antibodies. The nitrocellulose mem-
branes were further processed for chemiluminescence detection
(Santa Cruz) by using horseradish peroxidase-conjugated goat
antirabbit secondary antibody diluted to 1000 (Santa Cruz) for
1 h at room temperature. Equal protein loading was confirmed
by stripping the membranes, and then immunoreacting with β-
actin (Millipore, #MAB1501) at a dilution of 1:2000, rabbit mon-
oclonal anti-mTOR (Millipore, #04-385) at a dilution of 1:1000,
Akt (Cell Signaling, #9272) at a dilution of 1:1000, p44/p42 ERK
(Millipore, #05-1152) at a dilution of 1:1000, or rabbit polyclonal
anti-AMPAR GluR1 (Millipore, #AB1504) at a dilution of 1:1000.
Optical densities were quantified using a computer-assisted pro-
gram (Gel-Pro Analyzer).
Statistical Analysis
Data of the animal studies were evaluated using a Student’s
t-test or one-way analysis of variance, followed by a Tukey post hoc
test, using SPSS 12.0 statistical software. All statistical tests were
two-tailed, and results were considered significant at p< 0.05.
Results
Effects of a Single Injection of Sarcosine
Compared with controls treated with saline, rats treated with sar-
cosine (560mg/kg) exhibited a significantly decreased immobility
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time in the FST (t= 4.404, df= 18, p< 0.001 on computer scor-
ing and t= 2.857, df= 18, p< 0.05 on manual scoring), with
concomitant significant increases in climbing behavior when
injected with sarcosine 30min before the FST (t= -2.545, df= 18,
p< 0.05) (Figures 2A,B). In addition, to examine whether sarco-
sine could increase spontaneous locomotor activity and yield a
false-positive result in the FST, the total closed arm entries and
distance moved in EPM were measured as an indicator of general
activity. However, sarcosine did not increase locomotor activity
(Figures 2C,D).
To determine whether the decreased immobility was accompa-
nied by increased activated mTOR signaling, the phosphorylated
and activated forms of mTOR and mTOR upstream regulator
proteins were assessed after acute sarcosine treatment. After the
treatment, rats showed significant increases in the immunoreac-
tivity of pmTOR, pERK, and pAkt, as would be expected with
antidepressant-like effects (Figure 2E). Total mTOR, ERK, and
Akt levels remained unchanged in vivo. Statistical analysis also
confirmed a significant increase in pmTOR activity in sarcosine-
treated rats (t= -253.445, df= 6, p< 0.001, Figure 2F). A similar
expression trendwas consistently observed in upstream regulators
such as pERK (t= -6.536, df= 6, p< 0.01, Figure 2G) and pAkt
(t= -3.741, df= 6, p< 0.05, Figure 2H).
Role of Activated AMPAR and mTOR Signaling in
the Antidepressant-Like Effects of Sarcosine
To determine the role of mTOR signaling and AMPAR
in antidepressant-like effects of sarcosine in the FST,
rapamycin, an mTOR inhibitor, and NBQX, an AMPAR
antagonist, were used. Similarly, acute sarcosine treatment
significantly reduced immobility [computer scoring main effect:
F(5,46)= 5.767; p< 0.001, Figure 3A; manual scoring main
effect: F(5,46)= 5.545; p< 0.001, Figure 3B] and increased
climbing behavior [manual scoring main effect: F(5,46)= 4.195;
p< 0.01, Figure 3B]. Pretreatment with rapamycin (20mg/kg,
i.p.) completely blocked the sarcosine-elicited antidepressant-like
effects of decreased immobility and increased climbing behavior
in the FST (p> 0.05 on both computer and manual scorings for
immobility; p> 0.05 on manual scoring for climbing behavior
between rapamycin/sarcosine- and saline/saline-treated groups in
Tukey post hoc analysis) (Figures 3A,B). In addition, a significant
difference was observed between rapamycin/sarcosine- and
saline/sarcosine-treated groups (p< 0.001 on computer
and manual scorings for immobility; p< 0.01 on manual
scoring for climbing behavior in Tukey post hoc analysis)
(Figures 3A,B). Similarly, pretreatment with NBQX (10mg/kg,
i.p.) reversed decreased immobility and increased climbing
behavior (p> 0.05 on both computer and manual scorings for
immobility; p> 0.05 on manual scoring for climbing behavior
between NBQX/sarcosine- and saline/saline-treated groups
in Tukey post hoc analysis) (Figures 3A,B). In addition, a
significant difference existed between NBQX/sarcosine- and
saline/sarcosine-treated groups (p< 0.05 on both computer
and manual scorings for immobility in Tukey post hoc analysis)
(Figures 3A,B). These data indicated that mTOR signaling and
AMPAR activations were required for the antidepressant-like
effects of sarcosine in the FST.
FIGURE 3 | The behaviors scored by computer (A) (percentage of
immobility time) and manually (B) (frequency of immobility, swimming,
climbing) of rats after acute sarcosine (560mg/kg, i.p.) administration
with pretreatment with NBQX (10mg/kg, i.p.) or rapamycin (20mg/kg,
i.p.) in FST test. Note that the decreased immobility and increased climbing
resulted from acute sarcosine treatment is blocked when rats were pretreated
with rapamycin. Similar effect is evidently observed when rats were pretreated
with NBQX. (*p<0.05; **p<0.01 compared with saline/saline-treated group;
#p<0.05, ##p<0.01 compared with saline/sarcosine-treated group with
Tukey post hoc analysis, Values shown are meanSEM, n= 8–9 per group).
Role of AMPAR–mTOR Signaling Pathway in the
Antidepressant-Like Effects of Sarcosine
We examined whether pretreatment with NBQX or rapamycin
would affect the activity of the mTOR signaling pathway
after sarcosine treatment. Similarly acute sarcosine treatment
significantly increased immunoreactivity of pmTOR, pERK,
and pAkt (Figure 4A). Total mTOR, ERK, and Akt levels
remained unchanged in vivo. NBQX administration 30min
before sarcosine treatment blocked the sarcosine-elicited
increase in the immunoreactivity of pmTOR [main effect:
F(3,12)= 17.534, p< 0.001; p< 0.01 between NBQX/sarcosine-
and saline/sarcosine-treated groups; p> 0.05 between
NBQX/sarcosine- and saline/saline-treated groups in Tukey
post hoc analysis; Figure 4B] as well as mTOR upstream regulator
signaling kinases pERK [main effect: F(3,12)= 29.692, p< 0.001;
p< 0.001 between NBQX/sarcosine- and saline/sarcosine-treated
groups; p> 0.05 between NBQX/sarcosine- and saline/saline-
treated groups in Tukey post hoc analysis; Figure 4C], and
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FIGURE 4 | Representative Western blotting (A) and relative expression
ratio of pmTOR (B), pERK (C), and pAkt (D) in the hippocampus of rats
after acute sarcosine (560mg/kg, i.p.) administration with pretreatment
with NBQX (10mg/kg, i.p.) or rapamycin (20mg/kg, i.p.). Western blots
analysis shows a notably increased expression of pmTOR, pERK, and pAkt in
rat hippocampus following acute sarcosine treatment. Note that the increased
expression of pmTOR, pERK, and pAkt resulted from acute sarcosine treatment
is blocked when rats were pretreated with NBQX. The increased expression of
pmTOR resulted from acute sarcosine treatment is blocked when rats were
pretreated with rapamycin and the increased expression of pERK and pAkt
resulted from acute sarcosine treatment is not blocked (*p<0.05; **p<0.01
compared with saline/saline-treated group; ##p<0.01, ###p<0.001 compared
with saline/sarcosine-treated group with Tukey post hoc analysis. Values shown
are meanSEM, n= 4 per group).
pAkt [main effect: F(3,12)= 14.969, p< 0.001; p< 0.001
between NBQX/sarcosine- and saline/sarcosine-treated groups;
p> 0.05 between NBQX/sarcosine- and saline/saline-treated
groups in Tukey post hoc analysis; Figure 4D] The increased
immunoreactivity of pmTOR after sarcosine treatment was
significantly abolished by pretreatment with rapamycin (p< 0.001
between rapamycin/saline- and saline/sarcosine-treated groups;
p> 0.05 between rapamycin/saline- and saline/saline-treated
groups in Tukey post hoc analysis; Figure 4B), but increased
pERK and pAkt expression caused by acute sarcosine treatment
was not blocked (both p> 0.05 between rapamycin/saline-
and saline/sarcosine-treated groups in Tukey post hoc analysis;
Figures 4C,D). These results suggested that sarcosine stimulated
the mTOR signaling pathway that was directly dependent on
AMPAR activation.
Role of Sarcosine Treatment in GluR1
Phosphorylation at the PKA Site
Glycine induces AMPAR membrane insertion in vitro (Lu et al.,
2001), and the insertion of GluR1/GluR2-containing AMPAR in
the neuronal membrane is controlled by the phosphorylation of
the AMPAR subunit of GluR1 on its PKA site (GluR1 Ser845)
(Banke et al., 2000; Esteban et al., 2003; Smith et al., 2006).
Previous studies have shown that the activation of GluR1 Ser845
is correlated with the effects of several antidepressants (Du et al.,
2006, 2007; Reus et al., 2011). Therefore, we determined whether
sarcosine, a GlyT1 inhibitor (Smith et al., 1992) and NMDAR
coagonist (Zhang et al., 2009), regulated the phosphorylation
of GluR1 Ser845 after an acute in vivo sarcosine treatment of
rats. Hippocampal phosphorylation states of GluR1 Ser845
were monitored in rats. The phosphorylation of hippocampal
GluR1 Ser845 was significantly increased after an acute in vivo
sarcosine treatment (t= -2.659, df= 6, p< 0.05; Figure 5A).
NBQX administration 30min before sarcosine treatment
reversed the sarcosine-elicited increase in the immunoreactivity
of pGluR1 Ser845 to the baseline. However, pretreatment
with rapamycin did not block the sarcosine-elicited increase
[main effect: F(3,12)= 26.324, p< 0.001; p> 0.05 between
NBQX/sarcosine- and saline/saline-treated groups; p< 0.001
between NBQX/sarcosine- and saline/sarcosine-treated groups;
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FIGURE 5 | Representative Western blotting of pGluR1 Ser845 from
hippocampal slices of rats treated with saline or sarcosine (A)
(560mg/kg, i.p.) and after acute sarcosine (560mg/kg, i.p.)
administration with pretreatment with NBQX (10mg/kg, i.p.) or
rapamycin (20mg/kg, i.p.) (B). Acute sarcosine treatment significantly
increases the expression of pGluR1 Ser845. The increased expression of
pGluR1 Ser845 resulted from acute sarcosine treatment is blocked when rats
were pretreated with NBQX (B). But, the effect was not blocked by pretreatment
with rapamycin (B). (*p<0.05; **p<0.01; ***p<0.001 compared with
saline/saline-treated group; ###p<0.001 compared with
saline/sarcosine-treated group with Tukey post hoc analysis. Values shown are
meanSEM, n= 4 per group).
p> 0.001 between rapamycin/sarcosine- and saline/saline-
treated groups; p> 0.05 between rapamycin/sarcosine- and
saline/sarcosine-treated groups in Tukey post hoc analysis;
Figure 5B]. Total GluR1 levels remained unchanged in vivo
(Figures 5A,B). These data indicated that sarcosine enhanced
AMPAR membrane insertion via an AMPAR throughput.
Discussion
Westudied the effects of sarcosine, aGlyT1 inhibitor andNMDAR
coagonist, at behavioral and molecular levels in rats. In addi-
tion, we demonstrated that a single injection of sarcosine exhib-
ited antidepressant-like effects in an FST depression model and
rapidly activated themTOR signaling pathway. Sarcosine-induced
antidepressant-like effects and increased mTOR signaling activa-
tion were significantly blocked by pretreatment with rapamycin
or NBQX. In addition, pretreatment with NBQX also eliminated
the ability of sarcosine to stimulate the activated form of mTOR
as well as mTOR upstream regulator signaling kinases ERK and
Akt. These results indicated that the antidepressant-like effects
of sarcosine occurred through the activated AMPAR–mTOR sig-
naling pathway. In addition, the phosphorylation of hippocampal
AMPAR subunit GluR1 at its PKA site (often considered an indi-
cator for GluR1membrane insertion in neurons) was significantly
increased after acute in vivo sarcosine treatment and abolished
by pretreatment with NBQX. These data also demonstrated that
sarcosine can enhance AMPAR membrane insertion through an
AMPAR throughput.
First, consistent with the results of our and previous studies of
NMDAR enhancers (Depoortere et al., 2005; Malkesman et al.,
2012; Huang et al., 2013), we observed that sarcosine exhibited
acute antidepressant-like effects in the FST (Figures 2A,B). Next,
we investigated changes in the activation of the mTOR signaling
pathway after a single injection of sarcosine.We observed that sar-
cosine rapidly increased the phosphorylated and activated forms
of mTOR as well as mTOR upstream regulator signaling kinases
ERK and Akt (Figures 2E–H). The direct role of mTOR signaling
in the antidepressant-like effects of sarcosine on rats in the FST
model was further examined using pretreatment with rapamycin,
which resulted in a complete blockade of the antidepressant-like
effects of sarcosine in the FST depression model (Figures 3A,B).
These results demonstrated that the activation of mTOR sig-
naling is necessary for the antidepressant-like effects of sar-
cosine. In addition, pretreatment with NBQX abolished the
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antidepressant-like effects of sarcosine (Figures 3A,B), demon-
strating a requirement for the stimulation of AMPAR activity. The
results demonstrated that sarcosine exerted rapid antidepressant-
like effectsmediated by the rapid activation of themTOR signaling
pathway and AMPAR stimulation.
Mammalian target of rapamycin is a serine/threonine protein
kinase involved in cell proliferation, mortality, survival, and pro-
tein synthesis (Hay and Sonenberg, 2004), and dysregulation of
its signaling cascade has been hypothesized to be a common
pathophysiological feature of neuropsychiatric disorders (Hoef-
fer and Klann, 2010a). Rapid activation of the mTOR signaling
pathway resulting in the rapid elevation of synapse-associated
proteins represents a mechanism for the rapid antidepressant
effect of the NMDAR antagonist ketamine (Li et al., 2010).
A similar phenomenon has been evidenced in recent studies
by using rapamycin blockade of metabotropic glutamate recep-
tor mGluR2/3 antagonist LY341495, mGluR5 antagonist MTEP,
mGluR7 agonist AMN082, and muscarinic receptor antagonist
scopolamine (Dwyer et al., 2012; Voleti et al., 2013; Koike and
Chaki, 2014; Palucha-Poniewiera et al., 2014). A postmortem
study also showed considerable deficits in mTOR signaling in
the prefrontal cortex of subjects diagnosed with major depres-
sive disorder (Jernigan et al., 2011). Accumulating evidence
suggests that the activation of mTOR signaling may be a con-
vergent change induced by antidepressant drugs. As expected
with antidepressant-like effects, our data are in agreement with
those of other studies providing evidence that sarcosine-induced
antidepressant-like effects are mediated by the activation of the
mTOR signaling pathway. Furthermore, we assessed the possible
involvement of AMPAR in the sarcosine-elicited activation of
the mTOR signaling pathway. Inhibiting the AMPAR antagonist
NBQX blocked the sarcosine-mediated induction of phospho-
rylated mTOR as well as mTOR upstream regulator signaling
kinases, ERK and Akt. Our findings clearly demonstrated that
the activation of the mTOR signaling pathway through AMPAR
is involved in the antidepressant-like effects of sarcosine and,
essentially, show a link with the mechanisms underlying the
antidepressant-like effects of ketamine (Li et al., 2010).
Similar to the NMDAR antagonist ketamine (Kugaya and
Sanacora, 2005; Maeng et al., 2008; Li et al., 2010), the
same antidepressant-like effects of sarcosine and other NMDAR
enhancers have been previously noted at the behavioral level
(Depoortere et al., 2005; Malkesman et al., 2012; Huang et al.,
2013). We extended the same effect to molecular levels that
demonstrated an increased sarcosine-elicited activation of the
AMPAR–mTOR signaling pathway. The question raised is why
the manipulation of the glutamatergic system by both NMDAR
enhancers and blockades improves the symptoms of depres-
sion and shares final common targets AMPAR and mTOR for
antidepressant effects. Preclinical evidence indicates that the
mechanisms underlying the antidepressant effects of NMDAR
antagonists are more complicated than those of a simple NMDAR
blockade (Maeng and Zarate, 2007; Maeng et al., 2008). This
finding suggests that the effects of ketamine are largely medi-
ated through the interplay between AMPAR and NMDAR, and
not through the NMDAR antagonist, thus finally inducing a
rapid AMPAR-mediated synaptic potentiation. An in vitro study
showed that AMPAR membrane insertion into the post-synaptic
membrane can be induced by the activation of synaptic NMDAR
with the coagonist glycine (Lu et al., 2001). The increased synaptic
availability of glycine because of glycine uptake inhibition caused
by sarcosine administration possibly facilitated AMPAR mem-
brane insertion in vivo, as shown in vitro, and subsequently upreg-
ulated the receptors that amplify post-synaptic AMPAR levels,
thus leading to increased AMPAR/NMDAR stimulation, previ-
ously hypothesized as a convergent mechanism for antidepressant
effects (Zarate et al., 2006a; Schloesser et al., 2008). Increased
AMPAR throughput may ultimately cause downstream neuro-
proliferative effects through the activation of mTOR and multi-
ple intracellular signaling cascades. Therefore, sarcosine exhibits
antidepressant-like effects as shown in Figure 6.
We examined the activation of GluR1 at the PKA site, an
indicator for GluR1 membrane insertion in neurons, for assessing
AMPAR trafficking into synapses after in vivo sarcosine treat-
ment. Our data indicated that acute in vivo sarcosine treatment
significantly increased the phosphorylation of GluR1 at the PKA
site, reflecting enhanced AMPAR insertion into the membrane
(Banke et al., 2000; Esteban et al., 2003; Smith et al., 2006). In addi-
tion, the sarcosine-elicited increased phosphorylation of GluR1
at the PKA site was blocked by NBQX pretreatment. These data
suggested that sarcosine enhanced AMPAR membrane insertion
through an AMPAR throughput. The results of this in vivo study
along with those of in vitro studies of glycine-induced AMPAR
insertion (Esteban et al., 2003; Smith et al., 2006) constitute
crucial evidence explaining why sarcosine, through an NMDAR
blockade, can exert antidepressant-like effects through the same
AMPAR–mTOR signaling pathway.
Although cellular and behavioral studies of synaptic plasticity
have demonstrated that the stimulation of mTOR signaling and
synaptic protein synthesis is dependent on AMPAR activation
(Hoeffer and Klann, 2010b; Livingstone et al., 2010), previous
in vitro studies have demonstrated thatmTORpredominantly reg-
ulates AMPAR trafficking (Wang et al., 2006), and mTOR activa-
tion increases the synaptic expression of various AMPAR subunits
(Wang et al., 2006), including GluA1/GluA2 (Peng et al., 2011),
GluR1 (Chen andNapoli, 2008; Slipczuk et al., 2009), andGluR2/3
(Wang et al., 2006). These results highlight a possible bidirectional
regulation of the AMPAR–mTOR signaling pathway. However,
our results showed that NBQX blocked the sarcosine-elicited
increase in the immunoreactivity of pGluR1 Ser845 (Figure 5) and
pmTOR (Figure 4B) as well as mTOR upstream regulator signal-
ing kinases pERK (Figure 4C) and pAkt (Figure 4D). However,
rapamycin could only block the increased immunoreactivity of
pmTOR (Figure 4B). Rapamycin treatment did not significantly
alter pGluR1 Ser845 levels (Figure 5) in sarcosine-treated rats.
This in vivo study showed that sarcosine-induced AMPAR mem-
brane insertion and mTOR activation required AMPAR activa-
tion; however, mTOR activation caused by sarcosine did not alter
AMPAR membrane insertion.
Although there are potential parallels between the antide-
pressant mechanisms of sarcosine and ketamine, there are
differences in the time scales in improving the depressive symp-
toms. Ketamine elicits an almost immediate antidepressant effect
(Zarate et al., 2006b). We previously showed that although
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FIGURE 6 | Proposed cellular mechanisms underlying
antidepressant-like effects of sarcosine. Sarcosine caused the
increased synaptic availability of glycine via inhibiting glycine uptake
facilitates. The activation of synaptic NMDAR with co-agonist glycine
induces AMPAR insertion into post-synaptic membrane that will amplify
post-synaptic AMPAR levels, leading to increased AMPAR/NMDAR
stimulation. Increased AMPAR throughput may ultimately cause
downstream neuroproliferative effects through the activation of mTOR and
multiple intracellular signaling cascades. Finally, sarcosine exhibit
antidepressant-like property.
sarcosine exhibited faster therapeutic efficacy than an SSRI did,
a longer time for onset of antidepressant effects (2–6weeks) was
observed with sarcosine treatment (Huang et al., 2013). Lamotrig-
ine and riluzole, which take several weeks to exert antidepressant
effects, show the same effects onAMPAR expression in vivo as sar-
cosine does (Du et al., 2007). Therefore, although a rapid increase
in AMPAR:NMDAR ratio may be a common cellular mechanism
of the antidepressant-like effect shared by sarcosine, ketamine,
lamotrigine, and riluzole and a rapidly activated mTOR signaling
pathway induced by a single dose of sarcosine in preclinical stud-
ies, only ketamine shows rapid onset of antidepressant action in
clinical studies. However, whether ketamine’s clinical rapidity of
action is attributable to a unique pharmacological characteristic,
and not only to the rapidly activated AMPAR–mTOR signaling
pathway showed in preclinical study, remains unknown; therefore,
more clinical studies are needed to elucidate the neurobiologi-
cal mechanisms underlying the different onset of antidepressant
action.
Although the activation of the AMPAR–mTOR signaling path-
way causes beneficial outcomes in the antidepressant-like effects
of sarcosine, enhanced mTOR signaling may also cause side
effects. The upregulated mTOR may accelerate tumor growth
(Shor et al., 2009). Sarcosine activated prostate cancer cells (Dahl
et al., 2011). Moreover, compared with benign prostate epithelial
cells, sarcosine levels were increased in invasive prostate cancer
cells (Sreekumar et al., 2009). Thus, there are safety clinical con-
cerns regarding the use of antidepressants with a potential to
enhance the mTOR signaling pathway, and further research is
required.
We demonstrated, for the first time, that the activation of
the AMPAR–mTOR signaling pathway after a single injection
of sarcosine is required to produce antidepressant-like effects in
the FST. In addition, sarcosine increased AMPAR membrane
insertion, thus supporting our hypothesis that sarcosine triggers
AMPAR membrane insertion, increases the AMPAR:NMDAR
ratio, and activates the mTOR signaling pathway. However, our
results would be more compelling if an entire series of studies
of depression-related behaviors was conducted. In addition, the
effects of sarcosine at behavioral and molecular levels were the
same as those of ketamine. However, sarcosine and ketamine
may have differential neurobiological effects in depression, and
further research on this discrepancy is required. Nevertheless, the
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present evidence offers new insight into the antidepressant effect
of glutamatergic system modulators, which may indicate an alter-
native glutamate-based approach for developing next-generation
antidepressants.
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